Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation - A multicenter, prospective, randomized trial

被引:218
作者
Yamaguchi, T [1 ]
机构
[1] Natl Cardiovasc Ctr, Hosp, Osaka 5658565, Japan
关键词
atrial fibrillation; cerebrovascular disorders; prevention; randomized controlled trials; warfarin;
D O I
10.1161/01.STR.31.4.817
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-The optimal intensity of warfarin therapy for secondary prevention of stroke in nonvalvular atrial fibrillation (NVAF) remains unclear. We studied the efficacy and safety of conventional- and low-intensity warfarin therapy in a prospective, randomized, multicenter trial. Methods-The study population consisted of patients with NVAF (<80 years old) who had a stroke or transient ischemic attack. The patients were randomly allocated into a conventional-intensity group (international normalized ratio [INR] 2.2 to 3.5) and a low-intensity group (INR 1.5 to 2.1). They were carefully monitored, and the annual rate of recurrent ischemic stroke and major hemorrhagic complications were compared between the groups. Results-We enrolled 115 patients (mean age 66.7+/-6.5 years) into the study. Fifty-five and 60 patients were allocated into the conventional- and low-intensity groups, respectively. The trial was stopped after a follow-up of 658 +/- 423 days, when major hemorrhagic complications occurred in 6 patients of the conventional-intensity group and the frequency (6.6% per year) was significantly higher than that in the low-intensity group (0% per year, P=0.01, Fisher's exact test). All of the 6 patients with major bleeding were elderly (mean age 74 years), and their mean INR before the major hemorrhage was 2.8. The annual rate of ischemic stroke was low in both groups (1.1% per year in the conventional-intensity group and 1.7% per year in the low-intensity groups) and did not differ significantly. Conclusions-For secondary prevention of stroke in persons with NVAF, especially in old patients, the low-intensity warfarin (INR 1.5 to 2.1) treatment seems to be safer than the conventional-intensity (INR 2.2 to 3.5) treatment.
引用
收藏
页码:817 / 821
页数:5
相关论文
共 18 条
[1]   ATRIAL-FIBRILLATION AND STROKE - 3 NEW STUDIES, 3 REMAINING QUESTIONS [J].
ALBERS, GW .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (13) :1443-1448
[2]  
Blackshear JL, 1996, LANCET, V348, P633
[3]   CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY [J].
CONNOLLY, SJ ;
LAUPACIS, A ;
GENT, M ;
ROBERTS, RS ;
CAIRNS, JA ;
JOYNER, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) :349-355
[4]   WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION [J].
EZEKOWITZ, MD ;
BRIDGERS, SL ;
JAMES, KE ;
CARLINER, NH ;
COLLING, CL ;
GORNICK, CC ;
KRAUSESTEINRAUF, H ;
KURTZKE, JF ;
NAZARIAN, SM ;
RADFORD, MJ ;
RICKLES, FR ;
SHABETAI, R ;
DEYKIN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) :1406-1412
[5]   Prevention of stroke in patients with nonvalvular atrial fibrillation [J].
Hart, RG ;
Sherman, DG ;
Easton, JD ;
Cairns, JA .
NEUROLOGY, 1998, 51 (03) :674-681
[6]   ORAL ANTICOAGULANT-THERAPY - URGENT NEED FOR STANDARDIZATION [J].
HIRSH, J .
CIRCULATION, 1992, 86 (04) :1332-1335
[7]   An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation [J].
Hylek, EM ;
Skates, SJ ;
Sheehan, MA ;
Singer, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (08) :540-546
[8]  
*JAP NONV ATR FIBR, 1996, JPN J STROKE, V18, P124
[9]  
KISTLER JP, 1990, NEW ENGL J MED, V323, P1505
[10]  
KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5